Vetoquinol
Develops and markets veterinary medicines
Account Manager, Contract Manufacturing - Pharmaceutical
Up to two days of telework per week; travel to CMO sites and other travel is required.
About the job
- A Master's degree in purchasing and/or supply chain, or an engineering degree with purchasing experience, together with initial purchasing experience in the industrial sector.
- Ideally, experience managing suppliers of products intended for sale in the chemical, pharmaceutical, cosmetic, or veterinary industry.
- Very good English proficiency at B2 level; additional languages are appreciated.
- Availability to travel to CMO sites and on other business travel.
- Comfort with handling figures and data.
- Strong autonomy, interpersonal ease, adaptability, listening skills, and negotiation ability.
- Manage purchasing activities and suppliers in the portfolio of contract manufacturing organizations producing veterinary pharmaceutical products, while complying with Group purchasing policies and applicable regulations.
- Coordinate sourcing and due diligence for selecting new contract manufacturing organizations and participate in make-or-buy evaluations.
- Negotiate manufacturing and supply contract terms and coordinate internally with legal, quality, supply chain, and technical functions.
- Coordinate internal support functions and contract manufacturing organizations, including quarterly business reviews.
- Communicate information internally and externally to support decision-making and the proper availability of products.
- Negotiate purchase prices, actions, and schedules for portfolio products to achieve optimal purchasing conditions.
- Maintain supplier relationships and ensure supplier information is created and maintained in the company supplier repository.
- Support ordering, payment, and dispute-resolution processes in collaboration with the legal department.
- Contribute to annual purchasing and operating budgets and monitor them with Management Control.
- Monitor the commercial, economic, quality, and supply performance of contract manufacturing organizations.
- Help rationalize the contract manufacturing organization and product portfolios.
- Calculate supplier key performance indicators and communicate them monthly through an entity dashboard.
- Conduct value analyses and propose purchasing cost reductions.
- Continuously identify and assess product-market-availability risks and define risk-reduction action plans.
- Analyze data and transactions using information systems and data-extraction tools.
- Participate in multifunctional and multicultural outsourcing projects and, when applicable, manage a multifunctional project team.
- Communicate project progress, maintain project tracking tables and indicators, and report assigned activities.
- Create or improve management processes, draft or apply procedures, propose action plans with schedules, communicate and substantiate results, and make recommendations.
- Experience managing suppliers of products intended for sale in the chemical, pharmaceutical, cosmetic, or veterinary industry.
- Knowledge of additional languages.
About the company
Vetoquinol is a global animal health company that develops and markets medicines and health products for pets and livestock. Its products are used to treat diseases, prevent illness, and support animal well-being, distributed through a network of subsidiaries and partners in about 24 direct countries with products available in around 100 countries. Core operations include research, development, and commercialisation of veterinary pharmaceuticals and health solutions for both companion and farm animals. What sets Vetoquinol apart is its long family-led history and steady international expansion, including an IPO in 2006 to accelerate growth, which has helped it build a widespread, multi-country presence. The company’s goal is to improve animal health globally by bringing effective veterinary products to markets around the world and expanding access through direct operations and partnerships.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Paris, France
Founded
1933
Get referred to Vetoquinol
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 sales rose 3.4% to €259 million, with U.S. sales up 13.1%.
- Net income climbed 22% to €30.5 million, and cash flow hit €59 million.
- Management plans new product launches for 2027, after simplifying complementary lines in 2026.
What critics are saying
- Q1 2026 sales were flat at constant rates, exposing fragile underlying momentum.
- Foreign exchange cuts hit €7.1 million in H1 2026, and India weakened.
- The 2025 FOLLTROPIN recall shows quality failures can trigger FDA scrutiny and brand damage.
What makes Vetoquinol unique
- Essential Products reached 64% of 2025 sales, sharpening Vetoquinol’s mix.
- Vetoquinol owns VetImpress and Command Centre ACT, embedding workflow software into practice management.
- The company’s U.S. rebound, plus onshore parasiticide manufacturing, strengthens control over supply and margins.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Disability Insurance
Paid Vacation
Commuter Benefits
Wellness Program
Professional Development Budget
Training Programs
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 2%Vetoquinol shares jump on 22% first-half profit increase. September 11, 2026 at 10:00 GMT EC Assets Editorial Vetoquinol shares surged significantly following the French animal health group's report of a 22% increase in first-half net income. The company also demonstrated strong cash flow generation during the period. This performance marks a return to growth for Vetoquinol in the first half of fiscal 2026. Vetoquinol's net income reached €30.5 million in the first half of 2026. This figure represents 11.8% of total sales for the period. The company's sales rose 3.4% at constant exchange rates to €259.3 million. MarketScreener reported revenue of €259m. Cash flow generation totaled €59 million. The growth was driven by strong performance in the U.S. market. Sales in the U.S. market increased by 13.1% in the first half. The company's results were achieved in an uncertain international environment. Vetoquinol Animal Health Sources: investing.com, morningstar.com, marketscreener.com, tipranks.com, app.dealroom.co.
Vetoquinol, a French animal health company, reported sales of €259 million for the first half of 2026, up 3.4% at constant exchange rates and 0.7% on a reported basis. Essential Products sales reached €169 million, growing 3.7% at constant exchange rates. The company posted earnings before interest and tax of €45 million, representing 17.3% of sales. Net income totalled €30 million, or 11.8% of sales. Cash flow generation was €59 million. Growth was driven by strong performance in the US market, where sales rose 13.1% in the first half. Essential Products now account for two-thirds of total sales. The company said it is preparing several new product launches.
Vetoquinol, a French animal health company, reported first-quarter 2026 sales of €125 million, down 4.3% on a reported basis but flat at constant exchange rates. Excluding currency effects and a product line simplification programme, sales increased 1.2% year-on-year. Exchange rate headwinds reached €5.2 million, primarily affecting the United States and India. The product line simplification programme impacted sales by €1.7 million. Essential products sales totalled €83 million, stable at constant exchange rates, whilst complementary products grew, driven by strong US performance. US sales rose 15.6% at constant exchange rates to €28 million. Companion animal products represented 71% of sales at €93 million, whilst farm animal products totalled €38 million. The company described 2026 as a transition year ahead of new product launches in 2027.
Vetoquinol launches Command Centre ACT. The platform creates 'clear accountability' and eases the administrative burden of tracking vaccinations and farm visits. A veterinary pharmaceutical company has launched a dashboard to help ease administrative burdens on farm and mixed practices and drive revenue growth and clinical compliance. Vetoquinol has launched Command Centre ACT, a dashboard extension for its VetImpress data management platform designed for clinical directors and business development staff. The extension is said to draw on practices' data stored within VetImpress or their practice management system to identify revenue opportunities and compliance gaps. Based on analysis using leptospirosis, bovine viral diarrhoea and infectious bovine rhinotracheitis, Vetoquinol estimates that in dairy herds alone, missed vaccination doses, lapsed vaccinations and unvaccinated herds demonstrate an opportunity of around £2,877 annually per farm vet. 'Strategic approach' As well as optimising vaccine scheduling and compliance, Command Centre ACT is said to address regulatory requirements such as Veterinary Medicines Requirements "animals under care" guidelines, automatically flagging farms that are due visits to visually inspect livestock. Vetoquinol product manager Andy Paine said: "The dashboard's name reflects its strategic approach to practice management. "Command Centre ACT enables the user to identify farms requiring attention and assign specific follow-up actions to individual vets through the VetImpress diary and tasks system, creating clear accountability whilst maintaining clinical focus. "We're ultimately selling accountability, but we're striking the right balance between management oversight and clinical autonomy." Work and well being 20 Apr 2026 Small animal 3 Mar 2026
Vetoquinol, a French veterinary pharmaceutical company, reported annual sales of €526 million for 2025, up 0.2% at constant exchange rates but down 2.5% on a reported basis. The company faced historically high negative currency impacts of €14.8 million and a €9.7 million decline from simplifying its Complementary product ranges. Essential Products sales reached €334.5 million, growing 4.1% at constant exchange rates, driven by a strong fourth quarter increase of 8.0%. The company completed transferring manufacturing of its parasiticide range to its own facilities. Essential Products now represent 64% of total sales, up from 61% in 2024. Companion animal products accounted for 72% of sales at €377 million, whilst farm animal products represented 28% at €149 million.